Clinical Trial Update: Safety Study Evaluating the Adrenal Suppression Potential of Product 0405 in Pediatric Subjects With Atopic Dermatitis [Phase 2]

View source ↗

Summary

Phase 2 safety trial in pediatric patients with atopic dermatitis to assess adrenal suppression potential of Product 0405.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Atopic Dermatitis

Drugs mentioned

• Product 0405

Snippet

Sponsor: Fougera Pharmaceuticals Inc. | Conditions: Atopic Dermatitis | Phase 2 | Status: COMPLETED